Skip to content
← All treatment topics

TREATMENT READING

Childhood Nasopharyngeal Cancer

Source sections for this topic, with the original link and date. Patient and professional reading are labelled separately.

Not medical advice · Not a complete treatment or trial directory

Made by Triangle.

Selected text from the National Cancer Institute, with the original link and date. Made by Triangle. This page is not an NCI PDQ summary. Source topics may be broader than an individual diagnosis.

Health professional

Special Considerations for the Treatment of Children With Cancer

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

Cancer in children and adolescents is rare, although the overall incidence has slowly increased since 1975.[1] Children and adolescents with cancer should be referred to medical centers that have a multidisciplinary team of cancer specialists with experience treating the cancers that occur during childhood and adolescence. This multidisciplinary team approach incorporates the skills of the following pediatric specialists and others to ensure that children receive treatment, supportive care, and rehabilitation to achieve optimal survival and quality of life:

Sources: 1

Primary care physicians.

Pediatric surgeons.

Pathologists.

Pediatric radiation oncologists.

Pediatric medical oncologists and hematologists.

Ophthalmologists.

Rehabilitation specialists.

Pediatric oncology nurses.

Social workers.

Child-life professionals.

Psychologists.

Nutritionists.

For specific information about supportive care for children and adolescents with cancer, see the summaries on Supportive and Palliative Care.

Sources: Supportive and Palliative Care

The American Academy of Pediatrics has outlined guidelines for pediatric cancer centers and their role in the treatment of children and adolescents with cancer.[2] At these centers, clinical trials are available for most types of cancer that occur in children and adolescents, and the opportunity to participate is offered to most patients and their families. Clinical trials for children and adolescents diagnosed with cancer are generally designed to compare potentially better therapy with current standard therapy. Other types of clinical trials test novel therapies when there is no standard therapy for a cancer diagnosis. Most of the progress in identifying curative therapies for childhood cancers has been achieved through clinical trials. Information about ongoing clinical trials is available from the NCI website.

Sources: 2 · NCI website

Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2020, childhood cancer mortality decreased by more than 50%.[3-5] Childhood and adolescent cancer survivors require close monitoring because side effects of cancer therapy may persist or develop months or years after treatment. For information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors, see Late Effects of Treatment for Childhood Cancer.

Sources: 3 · 5 · Late Effects of Treatment for Childhood Cancer

Childhood cancer is a rare disease, with about 15,000 cases diagnosed annually in the United States in individuals younger than 20 years.[6] The U.S. Rare Diseases Act of 2002 defines a rare disease as one that affects populations smaller than 200,000 people in the United States. Therefore, all pediatric cancers are considered rare.

Sources: 6 · Rare Diseases Act of 2002

The designation of a rare tumor is not uniform among pediatric and adult groups. In adults, rare cancers are defined as those with an annual incidence of fewer than six cases per 100,000 people. They account for up to 24% of all cancers diagnosed in the European Union and about 20% of all cancers diagnosed in the United States.[7,8] In children and adolescents, the designation of a rare tumor is not uniform among international groups, as follows:

Sources: 7 · 8

A consensus effort between the European Union Joint Action on Rare Cancers and the European Cooperative Study Group for Rare Pediatric Cancers estimated that 11% of all cancers in patients younger than 20 years could be categorized as very rare. This consensus group defined very rare cancers as those with annual incidences of fewer than two cases per 1 million people. However, three additional histologies (thyroid carcinoma, melanoma, and testicular cancer) with incidences of more than two cases per 1 million people were also included in the very rare group due to a lack of knowledge and expertise in the management of these tumors.[9]

Sources: 9

The Children's Oncology Group defines rare pediatric cancers as those listed in the International Classification of Childhood Cancer subgroup XI, which includes thyroid cancers, melanomas and nonmelanoma skin cancers, and multiple types of carcinomas (e.g., adrenocortical carcinomas, nasopharyngeal carcinomas, and most adult-type carcinomas such as breast cancers and colorectal cancers).[10] These diagnoses account for about 5% of the cancers diagnosed in children aged 0 to 14 years and about 27% of the cancers diagnosed in adolescents aged 15 to 19 years.[4] Most cancers in subgroup XI are either melanomas or thyroid cancers, with other cancer types accounting for only 2% of the cancers diagnosed in children aged 0 to 14 years and 9.3% of the cancers diagnosed in adolescents aged 15 to 19 years.

Sources: 10 · 4

These rare cancers are extremely challenging to study because of the relatively few patients with any individual diagnosis, the predominance of rare cancers in the adolescent population, and the small number of clinical trials for adolescents with rare cancers.

Information about these tumors may also be found in sources relevant to adults with cancer, such as Nasopharyngeal Carcinoma Treatment.

Sources: Nasopharyngeal Carcinoma Treatment

This page is made by Triangle. The reading above is selected source text, not a treatment recommendation, and it is not medical advice.

Health professional

Treatment of Newly Diagnosed Childhood Nasopharyngeal Carcinoma

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

The European Cooperative Study Group for Pediatric Rare Tumors within the PARTNER project (Paediatric Rare Tumours Network–European Registry) have published comprehensive recommendations for the diagnosis and treatment of nasopharyngeal carcinoma in children and adolescents.[1]

Sources: 1

Treatment options for newly diagnosed nasopharyngeal carcinoma include the following:

Combined-modality therapy with chemotherapy and radiation therapy.

Sources: Combined-modality therapy with chemotherapy and radiation therapy

Surgery.

Sources: Surgery

Immunotherapy with checkpoint inhibitors.

Sources: Immunotherapy with checkpoint inhibitors

Health professional · Treatment of Newly Diagnosed Childhood Nasopharyngeal Carcinoma

Combined-Modality Therapy With Chemotherapy and Radiation Therapy

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

High-dose radiation therapy alone has a role in managing nasopharyngeal carcinoma. However, studies (in both children and adults) show that combined-modality therapy with chemotherapy and radiation is the most effective way to treat nasopharyngeal carcinoma.[2]

Sources: 2

Multiple studies have investigated the role of chemotherapy in the treatment of adult patients with nasopharyngeal carcinoma. The use of concomitant chemoradiation therapy has been consistently associated with a significant survival benefit, including improved locoregional disease control and reduction in distant metastases.[2] The addition of neoadjuvant or adjuvant chemotherapy to concomitant chemoradiation has further improved outcomes. The Meta-Analysis of Chemotherapy in Nasopharyngeal Carcinoma (MAC-NPC) collaborative group presented an analysis of 26 trials that included 7,080 patients. The results showed that the addition of chemotherapy to radiation therapy reduced the risk of death, and that the hazard ratio (HR) for risk of death was lowest for adjuvant or neoadjuvant chemotherapy combined with concurrent chemoradiation therapy, compared with concurrent chemoradiation therapy alone.[3]

Sources: 2 · 3

In adult patients, recent studies investigated the use of neoadjuvant gemcitabine and cisplatin. A phase III study compared concurrent chemoradiation therapy with or without induction therapy using gemcitabine plus cisplatin for patients with locally advanced nasopharyngeal carcinoma. The study found a significant improvement in overall survival (OS) for patients who received induction chemotherapy with gemcitabine plus cisplatin, compared with those who did not receive induction chemotherapy (5-year OS rates, 87.9% vs. 78.8%; HR, 0.51; 95% confidence interval, 0.34–0.78; P = .001).[4,5]

Sources: 4 · 5

In children, most studies have used neoadjuvant chemotherapy with cisplatin and fluorouracil (5-FU) followed by concomitant chemoradiation with single-agent cisplatin.[6-8][Level of evidence B4]; [9] Using this approach, 5-year OS rate estimates are consistently above 80%.[7-9] The following two modifications of this approach have been investigated:

Sources: 6 · 8 · Level of evidence B4 · 9 · 7 · 9

The German Society of Pediatric Oncology and Hematology (GPOH) NPC-2003 study included a 6-month maintenance therapy phase with interferon-beta. The study reported a 30-month OS rate estimate of 97.1%.[7]

Sources: 7

A randomized prospective trial compared cisplatin and 5-FU with and without docetaxel.[8][Level of evidence A1] The addition of docetaxel was not associated with improved outcomes.

Sources: 8 · Level of evidence A1

For adults with nasopharyngeal carcinoma, gemcitabine plus cisplatin has been shown to be more effective than 5-FU plus cisplatin, both in front-line and recurrent settings.[10,11]

Sources: 10 · 11

While nasopharyngeal carcinoma is a very chemosensitive neoplasm, high radiation doses to the nasopharynx and neck (approximately 65–70 Gy) are required for optimal locoregional control.[12-14] However, in children, studies using neoadjuvant chemotherapy have shown that it is possible to reduce the radiation dose to 55 Gy or 60 Gy for good-responding patients.[6,7,15] The GPOH reviewed 45 patients enrolled in the NPC-2003 study and an additional 21 patients who were subsequently treated per the NPC-2003 trial.[16] The 66 patients with locoregionally advanced nasopharyngeal carcinoma had an event-free survival (EFS) rate of 93.6% and an OS rate of 96.7% after a median follow-up of 73 months. Seven patients who had complete responses after induction therapy received a reduced radiation dose of 54 Gy. None of these patients experienced a relapse. In young patients with advanced locoregional nasopharyngeal carcinoma, excellent long-term survival rates can be achieved using multimodal treatment, including interferon-beta. Radiation doses may be reduced in patients with complete remission after induction chemotherapy. Reduced radiation doses may limit late effects related to radiation exposure.

Sources: 12 · 14 · 6 · 7 · 15 · 16

The Children's Oncology Group performed a prospective trial to evaluate the impact of induction chemotherapy and concurrent chemoradiation therapy.[9] Patients were scheduled to receive three cycles of induction chemotherapy with cisplatin and 5-FU, followed by chemoradiation therapy with three cycles of cisplatin. Patients with complete or partial responses to induction chemotherapy received 61.2 Gy of radiation to the nasopharynx and neck, and patients with stable disease received 71.2 Gy of radiation. After a feasibility analysis, the study was amended to reduce cisplatin to two cycles during chemoradiation therapy. Results of the study include the following:

Sources: 9

The 5-year EFS rate estimate was 84.3%, and the OS rate estimate was 89.2%.

The 5-year EFS rates were 100% for patients with stage IIb disease, 82.8% for patients with stage III disease, and 82.7% for patients with stage IV disease.

The 5-year cumulative incidence estimates of local, distant, and combined relapses were 3.7%, 8.7%, and 1.8%, respectively.

Patients who were treated with three chemoradiation therapy cycles of cisplatin were observed to have higher 5-year postinduction EFS rates than patients who were treated with two cycles, although the difference was not statistically significant (90.7% vs. 81.2%; P = .14).

The combination of cisplatin-based chemotherapy and high doses of radiation therapy to the nasopharynx and neck are associated with a high probability of hearing loss, hypothyroidism and panhypopituitarism, trismus, xerostomia, dental problems, and chronic sinusitis or otitis.[6,17,18]; [19][Level of evidence C1] The use of proton radiation therapy may reduce the toxicity to the brain and skull base region without compromising disease control.[20] For more information, see Late Effects of Treatment for Childhood Cancer.

Sources: 6 · 17 · 18 · 19 · Level of evidence C1 · 20 · Late Effects of Treatment for Childhood Cancer

In a group of 549 pediatric patients with nasopharyngeal carcinoma diagnosed between 2005 and 2021, recursive partitioning (i.e., successive grouping) was performed based on stage and Epstein-Barr virus (EBV) viral load. This resulted in three groups of patients: low-risk patients, intermediate-risk patients, and high-risk patients.[21]

Sources: 21

Intermediate-risk patients (stage IVa nasopharyngeal carcinoma and <4,000 copies/mL of EBV) had significant responses with induction chemotherapy followed by concurrent chemotherapy and radiation therapy. Their progression-free survival (PFS) and distant metastases‒free survival rates were significantly improved, compared with those who received only concurrent chemotherapy and radiation therapy.

In contrast, there were no significant differences between these two treatment regimens in low-risk and high-risk patients.

Health professional · Treatment of Newly Diagnosed Childhood Nasopharyngeal Carcinoma

Surgery

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

Surgery has a limited role in the management of nasopharyngeal carcinoma. The disease is usually considered unresectable because of extensive local spread.

Health professional · Treatment of Newly Diagnosed Childhood Nasopharyngeal Carcinoma

Immunotherapy With Checkpoint Inhibitors

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

The U.S. Food and Drug Administration (FDA) approved the anti-PD-1 monoclonal antibody toripalimab-tpzi in combination with cisplatin and gemcitabine for first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The approval was based on the results of a phase III placebo-controlled clinical trial. Patients received toripalimab-tpzi or placebo in combination with gemcitabine plus cisplatin every 3 weeks for up to six cycles, followed by monotherapy with toripalimab-tpzi or placebo. Patients randomly assigned to receive toripalimab-tpzi had superior PFS and OS rates. The 1-year and 2-year PFS rates were 59.0% versus 32.9% and 44.8% versus 25.4% in the toripalimab-tpzi and placebo groups, respectively. Corresponding OS rates at 2 years were 78.0% versus 65.1%, respectively. At 3 years, the OS rates were 64.5% versus 49.2%, respectively.[22][Level of evidence B1]

Sources: 22 · Level of evidence B1

Health professional · Treatment of Newly Diagnosed Childhood Nasopharyngeal Carcinoma

Treatment Options Under Clinical Evaluation for Newly Diagnosed Childhood Nasopharyngeal Carcinoma

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

The following is an example of a national and/or institutional clinical trial that is currently being conducted:

ARAR2221 (NCT06064097) (A Study Using Nivolumab, in Combination with Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma): This study will evaluate the safety of combining induction chemotherapy with an anti-PD-1 immune checkpoint inhibitor (nivolumab) in children, adolescents, and young adults with nasopharyngeal carcinoma. It will also estimate the 2-year EFS rate of patients treated with induction chemoimmunotherapy using gemcitabine and cisplatin, followed by consolidation chemotherapy, radiation therapy, immunotherapy (cisplatin, nivolumab, and response-adjusted, dose de-escalated radiation therapy), and nivolumab maintenance therapy. The treatment plan in the ARAR2221 trial was modeled after therapy that was effective in phase III trials for adults with nasopharyngeal carcinoma.

Sources: ARAR2221 (NCT06064097)

Health professional

Treatment of Relapsed or Refractory Childhood Nasopharyngeal Carcinoma

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

The outcome is poor for patients with relapsed or refractory nasopharyngeal carcinoma, and most patients present with distant metastases.

Treatment options for relapsed or refractory nasopharyngeal carcinoma include the following:

Chemotherapy.

Sources: Chemotherapy

Immunotherapy.

Sources: Immunotherapy

Health professional · Treatment of Relapsed or Refractory Childhood Nasopharyngeal Carcinoma

Chemotherapy

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

Long-term remissions can be achieved with conventional chemotherapy. In a retrospective review of 14 pediatric patients with relapsed nasopharyngeal carcinoma who were treated with varying chemotherapy regimens, the 3-year event-free survival rate was 34%, and the overall survival rate was 44%.[1]

Sources: 1

Health professional · Treatment of Relapsed or Refractory Childhood Nasopharyngeal Carcinoma

Immunotherapy

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

Given the unique pathogenesis of nasopharyngeal carcinoma, immunotherapy has been explored for patients with refractory disease, as follows:

The use of Epstein-Barr virus (EBV)–specific cytotoxic T-lymphocyte therapy is a promising approach, with minimal toxicity and evidence of significant antitumor activity in patients with relapsed or refractory nasopharyngeal carcinoma.[2] In a phase I/II study of EBV-specific cytotoxic T-lymphocyte therapy in patients with refractory disease, response rates were observed in 33.3% of patients. Long-term remissions were obtained in 62% of patients treated in their second or subsequent remission.[3]

Sources: 2 · 3

Anti–programmed death 1 (PD-1) and programmed death-ligand 1 (PD-L1) monoclonal antibodies have been studied in adults with refractory nasopharyngeal carcinoma. In a meta-analysis that included nine studies and 842 patients with recurrent or metastatic nasopharyngeal carcinoma who received PD-1 inhibitors, the objective response rate was 24% (95% confidence interval [CI], 21%–26%), the 1-year progression-free survival rate was 25% (95% CI, 18%–32%), and the 1-year overall survival rate was 53% (95% CI, 37%–68%).[4]

Sources: 4

Health professional · Treatment of Relapsed or Refractory Childhood Nasopharyngeal Carcinoma

Treatment Options Under Clinical Evaluation for Relapsed or Refractory Childhood Nasopharyngeal Carcinoma

Source: Childhood Nasopharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: August 23, 2024. Captured 2026-09-09.

Information about National Cancer Institute (NCI)–supported clinical trials can be found on the NCI website. For information about clinical trials sponsored by other organizations, see the ClinicalTrials.gov website.

Sources: NCI website · ClinicalTrials.gov website

For patients

Types of treatment for childhood nasopharyngeal cancer

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

For patients · Types of treatment for childhood nasopharyngeal cancer

Who treats children with nasopharyngeal cancer?

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

A pediatric oncologist, a doctor who specializes in treating children with cancer, oversees treatment of nasopharyngeal cancer. The pediatric oncologist works with other health care providers who are experts in treating children with cancer and who specialize in certain areas of medicine. Other specialists may include:

pediatrician

Sources: pediatrician

pediatric surgeon

Sources: pediatric surgeon

radiation oncologist

Sources: radiation oncologist

ear, nose, and throat specialist

Sources: ear, nose, and throat specialist

pathologist

Sources: pathologist

pediatric nurse specialist

Sources: pediatric nurse specialist

social worker

Sources: social worker

rehabilitation specialist

Sources: rehabilitation specialist

psychologist

Sources: psychologist

child-life specialist

Sources: child-life specialist

For patients · Types of treatment for childhood nasopharyngeal cancer

Treatment options

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

There are different types of treatment for children and adolescents with nasopharyngeal cancer. You and your child’s care team will work together to decide treatment. Many factors will be considered, such as your child’s overall health and whether the cancer is newly diagnosed or has come back.

Your child’s treatment plan will include information about the cancer, the goals of treatment, treatment options, and the possible side effects. It will be helpful to talk with your child’s care team before treatment begins about what to expect. For help every step of the way, visit our booklet, Children with Cancer: A Guide for Parents.

Sources: Children with Cancer: A Guide for Parents

The types of treatment your child might have include:

For patients · Types of treatment for childhood nasopharyngeal cancer / Treatment options

Chemotherapy

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Chemotherapy (also called chemo) uses drugs to stop the growth of cancer cells. Chemotherapy either kills the cancer cells or stops them from dividing. Chemotherapy may be given alone or with other types of treatment, such as radiation therapy.

Chemotherapy for nasopharyngeal cancer is injected into a vein. When given this way, the drugs enter the bloodstream to reach cancer cells throughout the body. Chemotherapy used alone or in combination to treat nasopharyngeal cancer in children include:

cisplatin

Sources: cisplatin

fluorouracil (5-FU)

Sources: fluorouracil (5-FU)

Other chemotherapy not listed here may also be used.

Learn more about how chemotherapy works, how it is given, common side effects, and more at Chemotherapy to Treat Cancer.

Sources: Chemotherapy to Treat Cancer

For patients · Types of treatment for childhood nasopharyngeal cancer / Treatment options

Radiation therapy

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Radiation therapy uses high-energy x-rays or other types of radiation to kill cancer cells or keep them from growing. Nasopharyngeal cancer is treated with external beam radiation therapy. This type of radiation therapy uses a machine outside the body to send radiation toward the area of the body with cancer. Radiation therapy may be given alone or with other treatments, such as chemotherapy.

Learn more about External Beam Radiation Therapy for Cancer and Radiation Therapy Side Effects.

Sources: External Beam Radiation Therapy for Cancer · Radiation Therapy Side Effects

For patients · Types of treatment for childhood nasopharyngeal cancer / Treatment options

Surgery

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Surgery to remove the tumor is done if the tumor has not spread throughout the nasal cavity and throat at the time of diagnosis.

For patients · Types of treatment for childhood nasopharyngeal cancer / Treatment options

Immunotherapy

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Immunotherapy uses a person's immune system to fight cancer. Interferon may be used to treat nasopharyngeal cancer.

Sources: Interferon

Learn more about Immunotherapy to Treat Cancer.

Sources: Immunotherapy to Treat Cancer

For patients · Types of treatment for childhood nasopharyngeal cancer / Treatment options

Clinical trials

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

For some children, joining a clinical trial may be an option. There are different types of clinical trials for childhood cancer. For example, a treatment trial tests new treatments or new ways of using current treatments. Supportive care and palliative care trials look at ways to improve quality of life, especially for those who have side effects from cancer and its treatment.

You can use the clinical trial search to find NCI-supported cancer clinical trials accepting participants. The search allows you to filter trials based on the type of cancer, your child's age, and where the trials are being done. Clinical trials supported by other organizations can be found on the ClinicalTrials.gov website.

Sources: clinical trial search · ClinicalTrials.gov

Learn more about clinical trials, including how to find and join one, at Clinical Trials Information for Patients and Caregivers.

Sources: Clinical Trials Information for Patients and Caregivers

For patients · Types of treatment for childhood nasopharyngeal cancer

Treatment of childhood nasopharyngeal cancer

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Treatment of newly diagnosed nasopharyngeal cancer in children may include:

Chemotherapy followed by chemotherapy and radiation therapy given at the same time. Interferon may also be given.

Surgery to remove the tumor.

Treatment of refractory or recurrent nasopharyngeal cancer is chemotherapy.

Sources: refractory · recurrent

Use our clinical trial search to find NCI-supported cancer clinical trials that are accepting patients. You can search for trials based on the type of cancer, the age of the patient, and where the trials are being done. General information about clinical trials is also available.

Sources: clinical trial search · General information

For patients

Side effects and late effects of treatment

Source: Childhood Nasopharyngeal Cancer (PDQ®)–Patient Version, National Cancer Institute.

Source updated: April 10, 2025. Captured 2026-09-09.

Cancer treatments can cause side effects. Which side effects your child might have depends on the type of treatment they receive, the dose, and how their body reacts. Talk with your child's treatment team about which side effects to look for and ways to manage them.

To learn more about side effects that begin during treatment for cancer, visit Side Effects.

Sources: side effects · Side Effects

Problems from cancer treatment that begin 6 months or later after treatment and continue for months or years are called late effects. Late effects of cancer treatment may include:

problems with the thyroid gland

Sources: thyroid gland

decreased mouth function

hearing loss or chronic ear infections

Sources: chronic

dental cavities

chronic sinusitis

Sources: sinusitis

changes in mood, feelings, thinking, learning, or memory

second cancers (new types of cancer) or other problems

Some late effects may be treated or controlled. It is important to talk with your child's doctors about the possible late effects caused by some treatments. Learn more about Late Effects of Treatment for Childhood Cancer.

Sources: Late Effects of Treatment for Childhood Cancer

Studies

A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)

NCT06064097 · RECRUITING · phase2

Stage II Nasopharyngeal Carcinoma AJCC v8, Stage III Nasopharyngeal Carcinoma AJCC v8, Stage IV Nasopharyngeal Carcinoma AJCC v8

ClinicalTrials.gov record

Disease and treatment settings

Childhood Nasopharyngeal Cancer

Disease and treatment setting

Treatment of Newly Diagnosed Childhood Nasopharyngeal Carcinoma

Childhood Nasopharyngeal Cancer

Disease and treatment setting

Nasopharyngeal Cancer in children and adolescents

refractory Childhood Nasopharyngeal Cancer

Disease and treatment setting

Treatment of Relapsed or Refractory Childhood Nasopharyngeal Carcinoma